What is the AHA guideline‑based management for an adult with chronic heart failure with reduced ejection fraction?

AHA Guideline-Based Management for Chronic Heart Failure with Reduced Ejection Fraction

Adults with chronic HFrEF should receive four-pillar guideline-directed medical therapy (GDMT) consisting of: (1) SGLT2 inhibitors, (2) ARNI (sacubitril-valsartan) or ACE inhibitors/ARBs, (3) evidence-based beta blockers (carvedilol, metoprolol succinate, or bisoprolol), and (4) mineralocorticoid receptor antagonists (MRAs), initiated rapidly and titrated to target doses within 6-12 weeks. 1, 2

Core Four-Pillar Therapy

The 2022 AHA/ACC/HFSA guidelines fundamentally transformed HFrEF management by establishing SGLT2 inhibitors as a foundational therapy alongside the traditional neurohormonal blockade agents 1. This represents a major shift from older guidelines that focused primarily on ACE inhibitors and beta blockers 3.

1. SGLT2 Inhibitors (Class 1 Recommendation)

• Start immediately upon HFrEF diagnosis, regardless of diabetes status
• Empagliflozin or dapagliflozin are the evidence-based options
• These reduce mortality, cardiovascular death, and HF hospitalizations by approximately 20-30% 1, 2
• No titration required; use standard dosing from initiation

2. ARNI/ACE Inhibitors/ARBs (Class 1 Recommendation)

• Preferred sequence: Start with ARNI (sacubitril-valsartan) over ACE inhibitors or ARBs when feasible 1, 2
• ARNI provides superior mortality reduction (approximately 20% additional benefit over enalapril)
• If using ACE inhibitors initially, switch to ARNI after stabilization
• Critical safety point: Allow 36-hour washout period when switching from ACE inhibitor to ARNI to avoid angioedema 1
• ARBs are reserved for patients intolerant to both ACE inhibitors (due to cough) and ARNI 3

ACE Inhibitor Initiation Protocol (if ARNI not immediately available):

• Review and reduce diuretics 24 hours before starting
• Begin with low dose, preferably in evening when supine
• Titrate to target doses proven in trials over 2-4 weeks
• Monitor BP, renal function, and potassium at 1-2 weeks after each dose increase, then at 3 months, then every 6 months 3
• Avoid NSAIDs and potassium-sparing diuretics during initiation 3

3. Evidence-Based Beta Blockers (Class 1 Recommendation)

• Only use: Carvedilol, metoprolol succinate, or bisoprolol—these are the only beta blockers proven to reduce mortality in HFrEF 1, 3
• Start at low doses in stable patients (not acutely decompensated)
• Titrate slowly to target doses over 8-12 weeks
• Provide 20% mortality reduction and reduce sudden cardiac death 3
• Continue even if LVEF improves above 40% 1, 2

4. Mineralocorticoid Receptor Antagonists (Class 1 Recommendation)

• Spironolactone or eplerenone
• Particularly critical in NYHA class III-IV patients, where they reduce mortality by 30% 3
• Monitoring requirements: Check potassium and creatinine at 5-7 days after initiation, then weekly until stable 3
• Hold if potassium >5.5 mEq/L or creatinine rises substantially
• Avoid if baseline potassium >5.0 mEq/L or GFR <30 mL/min

Diuretic Management

Loop diuretics are essential for symptomatic relief when fluid overload is present but do not improve survival 3. They should always be combined with the four-pillar GDMT, not used as monotherapy.

Diuretic Algorithm:

• Initial treatment: Loop diuretics (furosemide, bumetanide, torsemide) for patients with congestion
• If GFR <30 mL/min, avoid thiazides except when combined synergistically with loop diuretics 3
• Insufficient response:
  • Increase loop diuretic dose
  • Administer twice daily dosing
  • Combine loop diuretic with thiazide
  • In severe refractory cases: add metolazone with frequent electrolyte monitoring 3

Secondary/Adjunctive Therapies

Digoxin (Class 2a-2b)

• Primary indication: Atrial fibrillation with any degree of HF to control ventricular rate 3
• Secondary indication: Persistent symptoms despite optimal GDMT in sinus rhythm (improves symptoms, does not reduce mortality) 3
• Dose: 0.125-0.25 mg daily (lower in elderly or renal impairment)
• Combination with beta blocker superior to either alone 3

Hydralazine-Isosorbide Dinitrate

• Consider in Black patients as add-on to standard GDMT (mortality benefit demonstrated in this population)
• Alternative for patients intolerant to all RAAS inhibitors/ARNI 1

Ivabradine

• For patients in sinus rhythm with heart rate ≥70 bpm despite maximally tolerated beta blocker
• Reduces HF hospitalizations 1

Vericiguat

• Newer option for patients with recent worsening HF despite GDMT
• Reduces cardiovascular death and HF hospitalization 1

Critical Management Principles

Rapid Initiation Strategy

Do not delay: All four pillars should be initiated as rapidly as tolerated, ideally within days to weeks of diagnosis, not sequentially over months 1, 2, 4. The outdated approach of "start and wait" has been replaced by aggressive early optimization.

Patients with Improved LVEF (>40%)

Continue all HFrEF therapies indefinitely—these patients remain at high risk and benefit from continued treatment 1, 2. The term "HF with improved EF" replaces "recovered" to emphasize ongoing need for therapy.

Monitoring for Adverse Effects

Hypotension:

• Asymptomatic hypotension (SBP >90 mmHg) is acceptable if patient tolerates therapy
• Reduce or eliminate non-essential vasodilators before reducing GDMT

Hyperkalemia:

• Optimize with dietary counseling, diuretic adjustment, and potassium binders (patiromer, sodium zirconium cyclosilicate) before discontinuing MRAs
• MRAs provide substantial mortality benefit that outweighs mild hyperkalemia risk

Worsening Renal Function:

• Modest creatinine elevation (up to 30% increase) is acceptable if stable
• Discontinue only if substantial, progressive deterioration occurs 3

Common Pitfalls to Avoid

1. Using non-evidence-based beta blockers (e.g., atenolol, metoprolol tartrate)—these lack mortality benefit 1, 3
2. Delaying ARNI initiation—start ARNI preferentially rather than planning to "switch later" 1, 2
3. Undertitrating medications—most patients receive suboptimal doses; push to target doses proven in trials 5, 4
4. Stopping GDMT when EF improves—this leads to relapse 1, 2
5. Avoiding MRAs due to fear of hyperkalemia—use potassium binders to enable MRA continuation 1
6. Prescribing NSAIDs—these worsen HF and interfere with RAAS inhibition 3

Device Therapy Considerations

• ICD: Consider for primary prevention in patients with LVEF ≤35% despite ≥3 months of optimal GDMT, NYHA class II-III, and life expectancy >1 year 1, 2
• CRT: For LVEF ≤35%, QRS ≥150 ms (especially LBBB pattern), NYHA class II-IV on GDMT 1, 2

Non-Pharmacological Management

• Sodium restriction: Moderate restriction (2-3 g/day) in symptomatic patients; avoid excessive restriction
• Fluid management: Self-monitoring of daily weights; avoid excessive fluid intake in severe HF
• Exercise: Cardiac rehabilitation and regular physical activity improve functional capacity and quality of life (not contraindicated in stable HF) 3
• Alcohol: Avoid excessive intake; complete abstinence if alcohol-induced cardiomyopathy 3
• Smoking cessation: Mandatory 3